EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China-Reference-Cited by-同舟云学术

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China

Published:2016-06 Issue: Volume:96 Page:87-92
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Xu Jianlin,Jin Bo,Chu Tianqing,Dong Xue,Yang Haitang,Zhang Yanwei,Wu Dan,Lou Yuqing,Zhang Xueyan,Wang Huiming,Han Baohui

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J. Clin.,2015

2. Annual report on status of cancer in China, 2011;Chen;Chin. J. Cancer Res.,2015

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib;Lynch;New Engl. J. Med.,2004

4. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014

5. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J. Thorac. Oncol.,2014

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta;Current Oncology;2024-07-31

2. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review;Journal of Thoracic Oncology;2024-07

3. Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer;Lung Cancer;2024-03

4. Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery;Heliyon;2023-11

5. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies;Cancer Treatment Reviews;2023-11